News coverage about Fulgent Genetics (NASDAQ:FLGT) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Fulgent Genetics earned a news sentiment score of 0.20 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.3017142264121 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

A number of research analysts have recently commented on FLGT shares. Zacks Investment Research lowered shares of Fulgent Genetics from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. ValuEngine upgraded shares of Fulgent Genetics from a “sell” rating to a “hold” rating in a research report on Monday, October 2nd. Piper Jaffray Companies restated a “buy” rating on shares of Fulgent Genetics in a research report on Tuesday, October 24th. Raymond James Financial lowered shares of Fulgent Genetics from an “outperform” rating to a “mkt perform” rating in a research report on Tuesday, November 7th. Finally, Credit Suisse Group reduced their price target on shares of Fulgent Genetics from $10.00 to $7.50 and set an “outperform” rating for the company in a research report on Tuesday, November 7th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $7.25.

Fulgent Genetics (NASDAQ:FLGT) traded up $0.15 on Friday, hitting $3.60. The stock has a market capitalization of $63.98, a PE ratio of 179.50 and a beta of 1.27. Fulgent Genetics has a 1-year low of $2.72 and a 1-year high of $13.90.

In other news, insider Ming Hsieh purchased 10,504 shares of Fulgent Genetics stock in a transaction dated Tuesday, November 14th. The stock was purchased at an average cost of $3.30 per share, for a total transaction of $34,663.20. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Insiders have bought a total of 33,488 shares of company stock valued at $112,769 over the last 90 days. Company insiders own 58.80% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Fulgent Genetics (FLGT) Stock Price” was first published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at

Fulgent Genetics Company Profile

Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.

Insider Buying and Selling by Quarter for Fulgent Genetics (NASDAQ:FLGT)

Receive News & Ratings for Fulgent Genetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.